Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1024-1029

  Boulanger, Luke ^a   Hauch, Ole ^b   Friedman, Mark ^c   Foster, Talia ^c   Dixon, Deirdre ^c   Wygant, Gail ^b   Menzin, Joseph ^c  

^a Boston Health Economics ^*  (United States)

^b ASTRAZENECA   (United Kingdom)

^c Boston Health Economics Inc   (United States)

Author keywords

Atrial fibrillation; Hemorrhage; Thromboembolism; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG EXPOSURE; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; PROTHROMBIN TIME; REIMBURSEMENT; THROMBOEMBOLISM; UNITED STATES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALIFORNIA; DATA INTERPRETATION, STATISTICAL; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HEMORRHAGE; HUMANS; MALE; MEDICAID; MIDDLE AGED; RISK; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 33745154864     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G408     Document Type: Article

References (23)

1. Heart disease and stroke statistics-2004 update. Dallas, TX: American Heart Association, 2003.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis (letter). Ann Intern Med 1999;131:492-501.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
6. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med 1999;159:1322-8.
7. Petersen P, Godtfredsen J, Boysen G. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-9.
8. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
9. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92.
10. Holahan J. Health status and the cost of expanding insurance coverage. Health Aff (Millwood) 2001;20:279-86.
11. Health care financing review: Medicare and Medicaid statistical supplement. Washington, DC: Department of Health and Human Services, 2003.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
13. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7.
14. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
15. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
18. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD -9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9.
19. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996;49:1429-33.
20. Bush D, Tayback M. Anticoagulation for nonvalvular atrial fibrillation: effects of type of practice on physicians' self-reported behavior. Am J Med 1998;104:148-51.
21. Johnston JA, Cluxton RJ, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH. Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 2003;163;1705-10.
22. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
23. Smalley WE, Ray WA, Daugherty JR, Griffin MR. No association between calcium channel blocker use and confirmed bleeding peptic ulcer disease. Am J Epidemiol 1998;148:350-4.